PhaseV

Read how adaptive trials promote more patient-focused clinical trials, ensuring clinical studies are designed to maximize patient benefits. Thank you Mike Walsh and Patient Advocacy Strategies for the collaboration on this important piece. For more information on adaptive clinical trials and the benefits they can bring to your trial - contact us at [email protected]

We're thrilled to share our latest research on Conditional Average Treatment Effects (CATE) estimation in clinical trials. CATE estimation provides crucial value of understanding treatment effect heterogeneity, which is inherent to designing patient-centered trials. Our extensive simulation study demonstrates the limitation of traditional methods and introduces novel ensemble methods, which present better results across diverse use cases, varying in complexity, sample size, and underlying mechanisms. These robust methods reveal the factors driving heterogeneity in the presence of multiple covariates and complex biological signals, across therapeutic areas and trial types. Understanding the factors driving the heterogeneity enables us to predict treatment effects and probability of success and extract actionable, clinically significant, and business-meaningful insights to maximize the success of the next trial. Oshri Machluf Raviv Pryluk Elad Berkman Tzviel Frostig Gal Shoham Levin Tomer Milo

We're pleased to introduce our novel Causal Responders Detection (CARD) method, detailed in our latest publication. CARD applies machine learning and causal tree techniques to identify individuals who benefit significantly from treatments, ensuring false discovery control in both RCTs and observational studies. This method refines our understanding of individual treatment responses, providing crucial insights for precision medicine development. Our simulations confirm CARD's effectiveness across various settings, enabling to apply this method across therapeutic areas and clinical phases. #PersonalizedMedicine #MachineLearning #ClinicalTrials #HealthcareInnovation Tzviel Frostig Oshri Machluf Elad Berkman Raviv Pryluk Amitay Kamber

At the #DIA2024? Don't miss our session on the adaptive and exciting future of recruitment optimization, understand how to tackle the most challenging obstacles in recruitment today, and leverage newly available technologies and trial design measures for successfully advancing recruitment. Wednesday 3:15 PT

Had a great time today at the #DIA chairing a session on Machine Learning and Simulation in Clinical Trials, presenting the V(5) MUST HAVE elements needed to leverage ML at scale in drug development, and how, at PhaseV, we managed to make it happen. 1. Generalisability 2. Validity 3. Explainability  4. Actionability 5. Statistical Guarantees I presented three recent use cases where we implemented these elements - Causal-ML for the transition from P2 to P3; ML Surrogate Endpoint For Adaptive Trials; and ML For Optimizing Trial Design. Thank you Sam Miller and Andrew Stelzer for a fascinating session, and the DIA session audience for great questions and a fruitful discussion.

Meet us at the #DIA2024 in San Diego starting today! Come say hello at booth 1232 and see how the power of ML can transform clinical trials as we know them

Today! Don't miss it! #DIA2024 Sam Miller Andrew Stelzer Raviv Pryluk

Come meet us at EULAR - European Alliance of Associations for Rheumatology this week in Vienna! Don't miss our poster session, presenting a case study on Use of Proprietary ML-Based Technology for Optimizing Adaptive Trials for Lupus - FRIDAY 9:30 https://lnkd.in/dGUQRJm2 To book a meeting at the conference with Elad Berkman and Dan Goldstaub - contact us at [email protected]

📣Join FDA and Clinical Trials Transformation Initiative (CTTI) August 6, 2024 (10:00 AM - 5:30 PM EDT) for a free hybrid public workshop on artificial intelligence (AI) in drug and biological product development. AI holds great potential to transform how drugs are developed, manufactured, and utilized. As with any innovation, AI use in drug development creates new and unique challenges that require both careful management and a risk-based regulatory framework that is built on sound regulatory science approaches. This public workshop will explore guiding principles that are being applied by innovators and regulators to promote the responsible use of AI in the development of safe and effective drugs. Register today ➡️ https://lnkd.in/eP99VH_2

We are thrilled to take part in the upcoming DIA 2024 in San Diego and lead sessions on the future of advanced clinical trials together with an amazing panel of experts. Raviv Pryluk Sam Miller Charles Fisher Tanya Russell Kirkpatrick Jenny Higley Sangeeta Bhattacharya Add the sessions to your DIA schedule here: https://sched.co/1Yg7c https://sched.co/1Yg7Q #DIA2024